TRUADVICE’s ARK Genomic Revolution ETF ARKG Stock Holding History

TRUADVICE’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-10,035	Closed	-$1.01M	–	278
2020 Q4	$1.01M	Buy	+10,035	New	+$800K	0.31%	82

Other funds holding ARKG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SDH

Sloy Dahl & Holst Vancouver, Washington $728M AUM 37.66% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

TRUADVICE's ARKG Position: Q1 2021 in Review

TRUADVICE sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2021, closing a stake of 10,035 shares — an estimated $1.01M sold.

TRUADVICE first reported a position in ARKG in Q4 2020 and held it in 1 quarter. The position peaked at $1.01M in Q4 2020. 505 funds tracked by Wall St. Rank hold ARKG as of Q1 2021.

TRUADVICE reported no remaining ARK Genomic Revolution ETF position as of Q1 2021 after selling out during the quarter.
TRUADVICE sold 10,035 ARK Genomic Revolution ETF shares in Q1 2021, an estimated $1.01M.
TRUADVICE first reported a position in ARK Genomic Revolution ETF in Q4 2020 and held it in 1 quarter.
TRUADVICE's ARK Genomic Revolution ETF position peaked at $1.01M in Q4 2020.
505 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2021.

Based on TRUADVICE's 13F filing for Q1 2021, filed 30 Apr 2021.